Diligence memo · auto-generated · as of July 2, 2026
Nasus Pharma Ltd
Nasus Pharma Ltd looks fair against its niche peers and is active on financing cadence.
Businessfiled
Nasus Pharma Ltd operates in Biotechnology, based in TEL AVIV.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nasus Pharma Ltd has raised $15M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $15M on 2026-02-10.
Most recent recorded round closed around 2026-02-10.
Valuation (modeled)modeled
Provath models Nasus Pharma Ltd at approximately $54M (range $30M–$70M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.69× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era. Within the normal band (69% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 5 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 63% of Biotechnology peers (4293 compared).
Modeled value ranks above 47% of those peers.
Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.